IP Library › Granted Patent US 12,552,851
Granted Patent B2
US 12,552,851 · App. 17/999,496 · Granted Feb 17, 2026

T cell receptors with VGLL1 specificity and uses thereof

Inventors: Gregory Lizée (Houston, TX); Cassian Yee (Houston, TX)
Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
C07K14/7051A61K35/17A61K45/06A61K47/6425A61P35/00C12N5/0636A61K38/00C12N2501/2321C12N2502/1121
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,552,851
App. No.
17/999,496
Granted
Feb 17, 2026
Kind
B2
Abstract

Provided herein are tumor-antigen VGLL1 specific T cell receptors. The TCR may be utilized in various therapies, such as autologous cell transplantation, to treat a cancer. Methods for expanding a population of T cells that target VGLL1 are also provided.

Claims (26)

1 . An engineered T cell receptor (TCR), wherein the TCR specifically binds Vestigial-like 1 (VGLL1) and comprises:

(a) alpha chain CDR1 (SEQ ID NO: 16), CDR2 (SEQ ID NO: 17), and CDR3 (SEQ ID NO: 18) and beta chain CDR1 (SEQ ID NO:21), CDR2 (SEQ ID NO:22), and CDR3 (SEQ ID NO:23);

(b) alpha chain CDR1 (SEQ ID NO: 39), CDR2 (SEQ ID NO: 40), and CDR3 (SEQ ID NO: 41) and beta chain CDR1 (SEQ ID NO:44), CDR2 (SEQ ID NO:45), and CDR3 (SEQ ID NO:46);

(c) alpha chain CDR1 (SEQ ID NO: 62), CDR2 (SEQ ID NO: 63), and CDR3 (SEQ ID NO: 64) and beta chain CDR1 (SEQ ID NO:67), CDR2 (SEQ ID NO:68), and CDR3 (SEQ ID NO:69); or

(d) alpha chain CDR1 (SEQ ID NO: 85), CDR2 (SEQ ID NO: 86), and CDR3 (SEQ ID NO: 87) and beta chain CDR1 (SEQ ID NO:90), CDR2 (SEQ ID NO:91), and CDR3 (SEQ ID NO:92).

2 . The TCR of claim 1 , wherein the TCR comprises alpha chain CDR1 (SEQ ID NO: 16), CDR2 (SEQ ID NO: 17), and CDR3 (SEQ ID NO: 18) and beta chain CDR1 (SEQ ID NO:21), CDR2 (SEQ ID NO:22), and CDR3 (SEQ ID NO: 23).

3 . The TCR of claim 2 , wherein the TCR comprises an alpha chain variable region other than the CDRs having at least 90% identity to the amino acid sequence of SEQ ID NO: 15 and a beta chain variable region other than the CDRs having at least 90% identity to the amino acid sequence of SEQ ID NO:20.

4 . The TCR of claim 1 , wherein the TCR comprises an alpha chain variable region other than the CDRs having at least 90% identity to the nucleotide sequence of SEQ ID NO:3 and a beta chain variable region other than the CDRs having at least 90% identity to the nucleotide sequence of SEQ ID NO:9.

5 . The TCR of claim 1 , wherein the TCR other than the CDRs has at least 90% identity to SEQ ID NO:13.

6 . The TCR of claim 1 , wherein the TCR comprises alpha chain CDR1 (SEQ ID NO: 39), CDR2 (SEQ ID NO: 40), and CDR3 (SEQ ID NO: 41) and beta chain CDR1 (SEQ ID NO:44), CDR2 (SEQ ID NO:45), and CDR3 (SEQ ID NO: 46).

7 . The TCR of claim 6 , wherein the TCR comprises an alpha chain variable region other than the CDRs having at least 90% identity to the amino acid sequence of SEQ ID NO: 38 and a beta chain variable region other than the CDRs having at least 90% identity to the amino acid sequence of SEQ ID NO:43.

8 . The TCR of claim 6 , wherein the TCR comprises an alpha chain variable region other than the CDRs having at least 90% identity to the nucleotide sequence of SEQ ID NO:26 and a beta chain variable region other than the CDRs having at least 90% identity to the nucleotide sequence of SEQ ID NO:32.

9 . The TCR of claim 6 , wherein the TCR other than the CDRs has at least 90% identity to SEQ ID NO:36.

10 . The TCR of claim 1 , wherein the TCR comprises alpha chain CDR1 (SEQ ID NO: 62), CDR2 (SEQ ID NO: 63), and CDR3 (SEQ ID NO: 64) and beta chain CDR1 (SEQ ID NO:67), CDR2 (SEQ ID NO:68), and CDR3 (SEQ ID NO: 69).

11 . The TCR of claim 10 , wherein the TCR comprises an alpha chain variable region other than the CDRs having at least 90% identity to the amino acid sequence of SEQ ID NO: 61 and a beta chain variable region other than the CDRs having at least 90% identity to the amino acid sequence of SEQ ID NO:66.

12 . The TCR of claim 10 , wherein the TCR comprises an alpha chain variable region other than the CDRs having at least 90% identity to the nucleotide sequence of SEQ ID NO:49 and a beta chain variable region other than the CDRs having at least 90% identity to the nucleotide sequence of SEQ ID NO:55.

13 . The TCR of claim 10 , wherein the TCR other than the CDRs has at least 90% identity to SEQ ID NO:59.

14 . The TCR of claim 1 , wherein the TCR comprises alpha chain CDR1 (SEQ ID NO: 85), CDR2 (SEQ ID NO: 86), and CDR3 (SEQ ID NO: 87) and beta chain CDR1 (SEQ ID NO:90), CDR2 (SEQ ID NO:91), and CDR3 (SEQ ID NO: 92).

15 . The TCR of claim 14 , wherein the TCR comprises an alpha chain variable region other than the CDRs having at least 90% identity to the amino acid sequence of SEQ ID NO: 84 and a beta chain variable region other than the CDRs having at least 90% identity to the amino acid sequence of SEQ ID NO:89.

16 . The TCR of claim 14 , wherein the TCR comprises an alpha chain variable region other than the CDRs having at least 90% identity to the nucleotide sequence of SEQ ID NO:72 and a beta chain variable region other than the CDRs having at least 90% identity to the nucleotide sequence of SEQ ID NO:78.

17 . The TCR of claim 14 , wherein the TCR other than the CDRs has at least 90% identity to SEQ ID NO:82.

18 . The TCR of claim 1 , wherein the engineered TCR binds HLA-A*0101.

19 . The TCR of claim 1 , wherein the TCR is further defined as a soluble TCR, wherein the soluble TCR does not comprise a transmembrane domain.

20 . The TCR of claim 1 , wherein the TCR is covalently bound to a therapeutic agent.

21 . A host cell engineered to express the TCR of claim 1 .

22 . A method of treating cancer in a subject comprising administering an effective amount of a population of TCR-engineered cells of claim 21 to the subject.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2023
From: LIZÉE, GREGORY; LEE, CASSIAN
To: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 064689/0188 →
Continuity (2)
Provisional Application 63028262 · May 21, 2020
Related Publication 20230212256A1 · Jul 6, 2023
References Cited (28)
US 7910109B2 · Carroll et al. · 2011 [cited by applicant]
US 8586006B2 · Hood et al. · 2013 [cited by applicant]
US 8617562B2 · Tsunoda et al. · 2013 [cited by applicant]
US 9061059B2 · Chakraborty et al. · 2015 [cited by applicant]
US 9089604B2 · Chakraborty et al. · 2015 [cited by applicant]
US 20140147432A1 · Bancel et al. · 2014 [cited by applicant]
US 20150224182A1 · Hunt et al. · 2015 [cited by applicant]
US 20200040079A1 · Lizée et al. · 2020 [cited by applicant]
KR 1020150050681A · 2015 [cited by applicant]
WO WO2003003906A2 · 2003 [cited by applicant]
WO WO2018067869A1 · 2018 [cited by applicant]
Bellone, S. et al., “Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer,” [cited by applicant]
Bradley, S. D. et al., “BRAF [cited by applicant]
Bradley, S. D. et al., “Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers,” [cited by applicant]
Bradley, S. D. et al., “Supplementary Information for: Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers,” [cited by applicant]
Extended European Search Report issued in European Application No. 17859215.0, mailed Jun. 9, 2020. [cited by applicant]
Jiao, S. et al., “A Peptide Mimicking VGLL4 Function Acts as a YAP Antagonist Therapy against Gastric Cancer,” [cited by applicant]
Li, Y. et al., “IL-21 Influences the Frequency, Phenotype, and Affinity of the Antigen-Specific CD8 T Cell Response,” [cited by applicant]
MD Anderson Cancer Center, “Researchers aim to overcome multiple obstacles in pancreatic cancer,” [cited by applicant]
PCT International Search Report and Written Opinion issued in International Application PCT/2017/055414, mailed on Jan. 9, 2018. [cited by applicant]
PCT International Search Report and Written Opinion issued in International Patent Application No. PCT/US2021/033619, mailed Dec. 23, 2021. [cited by applicant]
PCT Preliminary Report on Patentability issued in International Patent Application No. PCT/US2021/033619, mailed Dec. 1, 2022. [cited by applicant]
Rizvi, N. et al., “Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer,” [cited by applicant]
Sonnemann, H. M. et al., “Vestigial-like 1 (VGLL1): An ancient co-transcriptional activator linking wing, placenta, and tumor development,” [cited by applicant]
Xu, Q-W. et al., “An integrated genome-wide approach to discover tumor-specific antigens as potential immunologic and clinical targets in cancer,” [cited by applicant]
Yarchoan, M. et al., “Tumor Mutational Burden and Response Rate to PD-1 Inhibition,” [cited by applicant]
Yoshida, T. et al., “Expression patterns of epiplakin1 in pancreas, pancreatic cancer and regenerating pancreas,” [cited by applicant]
Young, K. et al., “Immunotherapy and pancreatic cancer: unique challenges and potential opportunities,” [cited by applicant]